Debiopharm International SA
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Subsidiary
- Established
- 1979-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://debiopharm.com
A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 60
- Registration Number
- NCT06395753
- Locations
- 🇧🇪
University Hospital Gent, Gent, Belgium
🇺🇸Bakersfield Institute of Advanced Urology, Bakersfield, California, United States
🇺🇸Urology Center of Southern California, Murrieta, California, United States
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 53
- Registration Number
- NCT06129539
- Locations
- 🇦🇷
Hospital de Niños Dr. Ricardo Gutierrez, Buenos Aires, Argentina
🇧🇷Instituto PENSI - Pesquisa e Ensino em Saúde Infantil, São Paulo, Brazil
🇧🇷CPQuali Pesquisa Clinica, São Paulo, Brazil
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 78
- Registration Number
- NCT05815160
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 132
- Registration Number
- NCT05765812
- Locations
- 🇺🇸
New York University Langone Medical Center, New York, New York, United States
🇺🇸David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 170
- Registration Number
- NCT05706129
- Locations
- 🇦🇺
UNSW Sydney, St Vincent's Hospital Sydney, Sydney, Australia
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷CHU de Grenoble-Alpes, Boulevard de la Chantourne, Grenoble, France
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 20
- Registration Number
- NCT05364944
- Locations
- 🇩🇰
Rigshospitalet, Endokrinologisk afdeling, Copenaghen, Denmark
🇫🇷AP-HP Hopital Bicetre, Le Kremlin-bicetre, France
🇫🇷AP-HM - Hôpital de la Conception, Service d'Endocrinologie et Centre de Référence des Maladies Rares de l'hypophyse, Marseille, France
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 155
- Registration Number
- NCT05109975
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Pamplona, Spain
🇺🇸South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
🇪🇸Institut Catala de Oncologia, Girona, Spain
A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 12
- Registration Number
- NCT04962724
- Locations
- 🇬🇧
Labcorp Clinical Research Unit, Leeds, United Kingdom
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 46
- Registration Number
- NCT04122625
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Partners Cancer Care, Boston, Massachusetts, United States
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 115
- Registration Number
- NCT03968653
- Locations
- 🇪🇸
Hospital Vall Hebrón, Unidad de Investigación en Terapia Molecular (UITM), Barcelona, Spain
🇳🇱Leiden University Medical Center, Dept. of Clinical Oncology, Leiden, Netherlands
🇪🇸Clinica Universidad de Navarra - Pamplona, Pamplona, Spain